Halozyme Therapeutics, Inc. (HALO) Posts Surprise Q2 Profit
Tweet
Share
E-mailGet Alerts HALO Hot Sheet
Price: $110.19 -0.51%
Revenue Growth %: +36.2%
Financial Fact:
Net income (loss): -28.95M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Revenue Growth %: +36.2%
Financial Fact:
Net income (loss): -28.95M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
Halozyme Therapeutics, Inc. (NASDAQ: HALO) reported Q2 EPS of $0.03, $0.16 better than the analyst estimate of ($0.13). Revenue for the quarter came in at $23.2 million versus the consensus estimate of $4.95 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- H.C. Wainwright Reiterates Buy Rating on Halozyme Therapeutics (HALO)
- Asana, Inc. (ASAN) Tops Q2 EPS by 1c; offers guidance
- John Wiley & Sons, Inc. (WLYB) Misses Q1 EPS by 2c ; Offers Guidance
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
